Haemoconcentration of cardiopulmonary bypass blood with Hemosep
Not Applicable
Completed
- Conditions
- Topic: CardiovascularSubtopic: Cardiovascular (all Subtopics)Circulatory SystemDisease: Cardiovascular
- Registration Number
- ISRCTN51513145
- Lead Sponsor
- Papworth Hospital NHS Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Adult patients undergoing elective or urgent coronary artery bypass graft surgery (CABG), heart valve surgery, or a combination of CABG and valve surgery will be included.; Target Gender: Male & Female ; Lower Age Limit 18 years
Exclusion Criteria
1. Patients under 18 years of age
2. Patients undergoing emergency surgery
3. Patients with a contraindication to either heparin, protamine or tranexamic acid
4. Patients who might not adequately understand verbal explanations or written information given in English, or who have special communication needs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Haematocrit; Timepoint(s): 30-60 minutes after transfusion of blood
- Secondary Outcome Measures
Name Time Method 1. To evaluate the efficacy of the Hemosep system in reducing allogenic blood transfusion in patients post CPB for cardiac surgery<br>2. To compare the early postoperative serum levels of red cells, platelets and leukocytes between conventionally treated patients and patients treated with the Hemosep system<br>3. To compare the early postoperative coagulation indices, clotting factor levels and platelet count between patients treated conventionally and patients treated with the Hemosep system<br>4. To evaluate the cost effectiveness of the Hemosep system in patients undergoing cardiac surgery